Correlation Between MEITUAN UNSPADR2B and Sinopharm Group

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both MEITUAN UNSPADR2B and Sinopharm Group at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining MEITUAN UNSPADR2B and Sinopharm Group into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between MEITUAN UNSPADR2B and Sinopharm Group Co, you can compare the effects of market volatilities on MEITUAN UNSPADR2B and Sinopharm Group and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in MEITUAN UNSPADR2B with a short position of Sinopharm Group. Check out your portfolio center. Please also check ongoing floating volatility patterns of MEITUAN UNSPADR2B and Sinopharm Group.

Diversification Opportunities for MEITUAN UNSPADR2B and Sinopharm Group

-0.52
  Correlation Coefficient

Excellent diversification

The 3 months correlation between MEITUAN and Sinopharm is -0.52. Overlapping area represents the amount of risk that can be diversified away by holding MEITUAN UNSPADR2B and Sinopharm Group Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sinopharm Group and MEITUAN UNSPADR2B is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on MEITUAN UNSPADR2B are associated (or correlated) with Sinopharm Group. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sinopharm Group has no effect on the direction of MEITUAN UNSPADR2B i.e., MEITUAN UNSPADR2B and Sinopharm Group go up and down completely randomly.

Pair Corralation between MEITUAN UNSPADR2B and Sinopharm Group

Assuming the 90 days trading horizon MEITUAN UNSPADR2B is expected to under-perform the Sinopharm Group. In addition to that, MEITUAN UNSPADR2B is 2.87 times more volatile than Sinopharm Group Co. It trades about -0.1 of its total potential returns per unit of risk. Sinopharm Group Co is currently generating about -0.06 per unit of volatility. If you would invest  254.00  in Sinopharm Group Co on November 2, 2024 and sell it today you would lose (4.00) from holding Sinopharm Group Co or give up 1.57% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy95.45%
ValuesDaily Returns

MEITUAN UNSPADR2B  vs.  Sinopharm Group Co

 Performance 
       Timeline  
MEITUAN UNSPADR2B 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days MEITUAN UNSPADR2B has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's fundamental indicators remain nearly stable which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.
Sinopharm Group 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Sinopharm Group Co are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Sinopharm Group may actually be approaching a critical reversion point that can send shares even higher in March 2025.

MEITUAN UNSPADR2B and Sinopharm Group Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with MEITUAN UNSPADR2B and Sinopharm Group

The main advantage of trading using opposite MEITUAN UNSPADR2B and Sinopharm Group positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if MEITUAN UNSPADR2B position performs unexpectedly, Sinopharm Group can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sinopharm Group will offset losses from the drop in Sinopharm Group's long position.
The idea behind MEITUAN UNSPADR2B and Sinopharm Group Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Other Complementary Tools

USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Bonds Directory
Find actively traded corporate debentures issued by US companies
Fundamental Analysis
View fundamental data based on most recent published financial statements
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation